First Time Loading...

Iterum Therapeutics PLC
NASDAQ:ITRM

Watchlist Manager
Iterum Therapeutics PLC Logo
Iterum Therapeutics PLC
NASDAQ:ITRM
Watchlist
Price: 1.59 USD 1.92%
Updated: Mar 28, 2024

Intrinsic Value

ITRM doesn't have a meaningful market cap.

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded... [ Read More ]

There is not enough data to reliably calculate the intrinsic value of ITRM.

Key Points:
ITRM Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of Iterum Therapeutics PLC's business.

What risks and challenges
does Iterum Therapeutics PLC face in the near future?

Summarize the latest earnings report
of Iterum Therapeutics PLC.

Provide P/E
for Iterum Therapeutics PLC and its competitors.

Financials

Balance Sheet Decomposition
Iterum Therapeutics PLC

Current Assets 38.5m
Cash & Short-Term Investments 35.9m
Other Current Assets 2.6m
Non-Current Assets 1.2m
PP&E 700k
Intangibles 400k
Other Non-Current Assets 100k
Current Liabilities 16.4m
Accounts Payable 5.5m
Accrued Liabilities 9.4m
Other Current Liabilities 1.5m
Non-Current Liabilities 19.9m
Long-Term Debt 19.6m
Other Non-Current Liabilities 300k
Efficiency

Earnings Waterfall
Iterum Therapeutics PLC

Revenue
0 USD
Operating Expenses
-44m USD
Operating Income
-44m USD
Other Expenses
12.9m USD
Net Income
-31.1m USD

Free Cash Flow Analysis
Iterum Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ITRM Profitability Score
Profitability Due Diligence

Iterum Therapeutics PLC's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Negative Free Cash Flow
Negative Operating Income
Negative Net Income
37/100
Profitability
Score

Iterum Therapeutics PLC's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

ITRM Solvency Score
Solvency Due Diligence

Iterum Therapeutics PLC's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
40/100
Solvency
Score

Iterum Therapeutics PLC's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ITRM Price Targets Summary
Iterum Therapeutics PLC

Wall Street analysts forecast ITRM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ITRM is 6.63 USD with a low forecast of 6.06 USD and a high forecast of 7.35 USD.

Lowest
Price Target
6.06 USD
281% Upside
Average
Price Target
6.63 USD
317% Upside
Highest
Price Target
7.35 USD
362% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ITRM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ITRM Price
Iterum Therapeutics PLC

1M 1M
+24%
6M 6M
+127%
1Y 1Y
+67%
3Y 3Y
-92%
5Y 5Y
-99%
10Y 10Y
-99%
Annual Price Range
1.59
52w Low
0.65
52w High
2.3
Price Metrics
Average Annual Return -66.6%
Standard Deviation of Annual Returns 17.93%
Max Drawdown -100%
Shares Statistics
Market Capitalization 20.7m USD
Shares Outstanding 13 435 400
Percentage of Shares Shorted 7.42%

ITRM Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Iterum Therapeutics PLC Logo
Iterum Therapeutics PLC

Country

Ireland

Industry

Pharmaceuticals

Market Cap

20.7m USD

Dividend Yield

0%

Description

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.

Contact

DUBLIN
DUBLIN
Fitzwilliam Court, 1St Floor, Leeson Close
+35316694820.0
http://www.iterumtx.com

IPO

2018-05-25

Employees

13

Officers

President, CEO & Director
Mr. Corey N. Fishman
Chief Financial Officer
Ms. Judith M. Matthews
Strategic Advisor & Director
Dr. Michael W. Dunne M.D.
Chief Medical Officer
Dr. Sailaja Puttagunta M.D.
Senior Vice President of Technical Operations
Mr. Tom Loughman Ph.D.
Senior Vice President of Legal Affairs & Secretary
Ms. Louise Barrett
Show More
Senior VP & Head of Clinical Development
Dr. Steven I. Aronin M.D.
Show Less

See Also

Discover More